Pulmonary surfactant (tensioactive)
Natural pulmonary surfactant suspension (porcine lung extract) for intratracheal administration, indicated for rescue treatment of Respiratory Distress Syndrome in premature infants, reducing associated mortality and pneumothoraces.
Also known as: Curosurf, surfactante, poractant alfa
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
No documented drug–drug interactions for this medicine.
Poractant alfa is given endotracheally to the newborn; food does not apply.
Not applicable (neonatal endotracheal administration).
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
No relevant interaction (neonatal endotracheal administration).
Not applicable.
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
Poractant alfa can be associated with pulmonary haemorrhage in the premature newborn, especially in the first days.
Watch for signs of pulmonary haemorrhage (bloody secretions, respiratory deterioration) after administration.
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
Poractant alfa is used precisely in neonatal respiratory distress syndrome; its administration requires close ventilatory monitoring.
Monitor oxygenation and ventilation after administration.
DailyMed approved label (CUROSURF, Chiesi USA; setID 99bef307-00bd-4379-9f45-ede1380e74d4).
Poractant alfa is given to the newborn via the endotracheal route; it is not used in the mother, but its neonatal indication is well established.
Not applicable to pregnancy; exclusively neonatal use (neonatal RDS).
Not applicable to breastfeeding (neonatal use).
No specific additional contraception.
EMC-UK (MHRA) — approved Poractant alfa SmPC: https://www.medicines.org.uk/emc/product/6450/smpc
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes alveoli against collapse; CUROSURF compensates the surfactant deficiency of preterm infants and restores pulmonary surface activity. In vitro, it lowers minimum surface tension to ≤ 4 mN/m.
Restoration of alveolar surface activity by direct intratracheal administration of porcine phospholipids and surfactant proteins (SP-B, SP-C), improving oxygenation and lung compliance.
Intratracheal administration (acts locally at the alveolus; no relevant systemic absorption).
Administered directly to the lung, where biophysical effects occur at the alveolar surface; no human pharmacokinetic studies characterize absorption, biotransformation or elimination.
Not applicable — no human pharmacokinetic studies; local action in the lung.
